J7670 Metaproterenol — HCPCS Reimbursement & Policy

HCPCS Level II code J7670 represents metaproterenol sulfate inhalation solution, a compounded unit-dose formulation (per 10 mg) designed for administration through durable medical equipment. This code is relevant for billing of inhaled bronchodilator therapy delivered via DME in home or outpatient settings and supports documentation of medication dispensing and administration for respiratory care. Nationally, accurate coding of compounded inhalation products matters for claims processing, coverage determinations, and tracking of medication utilization in ambulatory and home-based respiratory services.

Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the medication, typical sites of service, and the aspects of billing that affect reimbursement and coverage. The publication outlines common modifiers associated with this billing area, discusses payer coverage considerations, and highlights where data is not available in the input. It also points to related code categories and service-line implications for home respiratory therapy and DME providers.

This summary is intended to help billing staff, clinical coders, and policy analysts understand the purpose of J7670, the service setting it represents, and the types of information to confirm when preparing claims.

Billing Code Overview

HCPCS Level II code J7670 describes metaproterenol sulfate, inhalation solution, compounded product, provided in unit dose form per 10 milligrams and administered through durable medical equipment (DME). The service type is inhalation medication administration via DME, and the typical site of service is home or other outpatient settings where DME is used.

Data not available in the input.

Clinical Context

A patient with acute bronchospasm secondary to asthma exacerbation presents to an outpatient infusion center or emergency department and requires nebulized short-acting bronchodilator therapy. The facility supplies a compounded metaproterenol sulfate inhalation solution in unit-dose form for administration through durable medical equipment (DME) such as a nebulizer. A respiratory therapist or trained nurse prepares the unit-dose and connects it to the patient’s nebulizer. The patient is monitored for bronchodilator response and adverse effects (tachycardia, tremor). After treatment, the clinician documents the medication name, J7670 as the administered HCPCS code, dose (per 10 mg unit), route (inhalation via DME), times administered, and clinical response. Billing follows facility outpatient or DME-supplied drug protocols and may include appropriate facility revenue codes and units reflecting the number of 10 mg unit doses used.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier / placeholder	Rarely submitted; not typically appended when another specific modifier applies.
`22`	Increased procedural services

Taxonomy Code	Specialty	Notes
`207RC0000X`	Pulmonary Disease	Pulmonologists commonly oversee inhaled bronchodilator therapy for respiratory exacerbations.
`363LP0200X`	Respiratory Therapy	Respiratory therapists prepare and administer nebulized unit-dose inhalation solutions.
`208D00000X`	Emergency Medicine	Emergency physicians initiate and manage acute bronchodilator therapy in the ED.
`245X00000X`	Nursing	Registered nurses often administer and monitor nebulized treatments in many settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J45.901`	Unspecified asthma, uncomplicated	Asthma exacerbations are a common indication for short-acting inhaled bronchodilators administered via nebulizer.
`J45.909`	Unspecified asthma, uncomplicated, unspecified	Used when unspecified asthma requires nebulized bronchodilator treatment.
`J44.1`	Chronic obstructive pulmonary disease with (acute) exacerbation	COPD exacerbations frequently require nebulized short-acting bronchodilator therapy.
`J20.9`	Acute bronchitis, unspecified	Acute bronchitis with bronchospasm may be treated with inhaled bronchodilators delivered via DME.
`R06.2`	Wheezing	Symptom code supporting the medical necessity for bronchodilator administration when bronchospasm is present.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction; including administration of nebulized bronchodilator therapy	Directly corresponds to the administration of a nebulized bronchodilator like metaproterenol delivered via DME; commonly billed for the treatment session.
`94664`	Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	Performed when teaching the patient correct use of a nebulizer device or unit-dose administration technique.
`99070`	Supplies and materials provided by the physician over and above those usually included with the office visit	Used for billing additional single-use supplies associated with compounded unit-dose medications if payer allows.
`94760`	Noninvasive ear or pulse oximetry for oxygen saturation; by single determination	Often performed alongside nebulized therapy to monitor oxygenation during treatment.
`99211`	Office or other outpatient visit for the evaluation and management of an established patient, minimal	Used when a brief nurse visit documents administration of inhaled therapy in a clinic setting.

OpenPayer

Summary & Overview

HCPCS Level II J7670: Metaproterenol Inhalation Solution, Unit Dose